Back To Search Instructions
Protocols
22 protocols meet the specified criteria
Disease Site: Ovary
Protocol No.TitleStatus
0600000477DATABASE FOR INDIVIDUALS AT HIGH RISK FOR BREAST, OVARIAN AND OTHER HEREDITARY CANCERSOpen
1000000475GOG 0252 A Phase III Clinical Trial of Bevacizumag with IV versus IP Chemotherapy in Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: NCI-Supplied Agent: Bevacizumab (NSC #704865, IND #7921)Closed
1000000857GOG0262_ A RANDOMIZED PHASE III TRIAL OF EVERY-3-WEEKS PACLITAXEL VERSUS DOSE DENSE WEEKLY PACLITAXEL IN COMBINATION WITH CARBOPLATIN WITH OR WITHOUT CONCURRENT AND CONSOLIDATION BEVACIZUMAB (NSC #704865, IND #7921) IN THE TREATMENT OF PRIMARY STAGE III OR IV EPITHELIAL OVARIAN, PERITONEAL OR FALLOPIAN TUBE CANCERClosed
1200000138Biospecimen Repository for Individuals at High Risk for Breast, Ovarian, or Other Hereditary CancersOpen
1200000320Chemotherapy Toxicity in Elderly Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer (GOG-0273)Closed
1200000556Can diet and physical activity modulate ovarian, fallopian tube and primary peritoneal cancer progression-free survival? (GOG-0225) (LIVES)Open
1404299159Imaging of the ovary with a volume holographic imaging system: pilot studyOpen
1411572748A Novel Method of Screening for Ovarian Cancer using Gynecologic Fluids and Mucus (USA-MCI GON-1.04)Closed
1504771536Continued Recruitment of High-Risk and Low-Risk control subjects to assess biomarkers of ovarian cancer riskOpen
1505838152A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch Maintenance Therapy Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerClosed
1602381312A PHASE 1A/B STUDY OF THE FOLIC ACID-TUBULYSIN CONJUGATE EC1456 IN PATIENTS WITH ADVANCED SOLID TUMORSNot Open
1607724485CYTOLOGICAL CHANGES AND MOLECULAR MECHANISM UNDERLYING THE ROLE OF FALLOPIAN TUBE EPITHELIUM IN THE DEVELOPMENT OF GYNECOLOGIC MALIGNANCYOpen
1610935809A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyOpen
1702240492A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed
1704390293A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsOpen
29027A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian CancerNot Open
PHXA-15-0002-10-15Can Diet and Physical Activity Modulate Ovarian Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?Open
PHXA-15-0028-80-15A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed
PHXA-16-0174-80-15A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian CancerOpen
PHXE-16-0213-80-15A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCEROpen
PHXE-17-0216-10-15EAY131: Molecular Analysis for Therapy Choice (MATCH) Open
PHXE-17-0349-10-15DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare TumorsOpen